Chester County News and Community Website
WAYNE, PA — Palvella Therapeutics, Inc. has announced the commencement of dosing in its Phase 3 SELVA trial, aimed at evaluating QTORIN™ 3.9% rapamycin anhydrous gel for treating microcystic lymphatic malformations …
Palvella Therapeutics Begins Phase 3 Trial for Microcystic Lymphatic Malformations Treatment Read More
RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) announced the swift completion of participant enrollment in its Launch-HTN trial, a critical component of its pivotal program investigating lorundrostat for the …
Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Pivotal Hypertension Trial Read More
WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has initiated patient enrollment for its SEISMiC C trial, targeting SCAI Stage C cardiogenic shock. This trial marks a pivotal step in …
Windtree Therapeutics Begins SEISMiC C Trial for Advanced Cardiogenic Shock Read More
WAYNE, PA — Teleflex Incorporated (NYSE: TFX) has announced the enrollment of the first patient in a new clinical study focused on the Barrigel™ rectal spacer. This major milestone marks …
Teleflex Inc. Enrolls First Patient in Barrigel™ Rectal Spacer Study Read More
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) is set to host an in-person Clinical Showcase on Tuesday, November 12, 2024, at the Nasdaq MarketSite in Times Square, New York City, …
Ocugen to Spotlight Gene Therapy Advances at Upcoming Clinical Showcase Read More
RADNOR, PA — Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) has announced that its Phase 3 TrustTSC trial, which evaluated the use of oral ganaxolone for treating seizures in individuals with tuberous …
Marinus Pharmaceuticals Faces Setback with Phase 3 TrustTSC Trial Read More
PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) has announced new data for its leading candidate, INO-3107, which could transform the treatment of recurrent respiratory papillomatosis (RRP). These findings, shared at the …
INOVIO Unveils Promising Data for INO-3107 in Treating RRP Read More
WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) has unveiled encouraging results from its ongoing Phase 1 trial of PRT3789, a groundbreaking SMARCA2 degrader, at the 36th Annual EORTC-NCI-AACR Symposium …
Prelude Therapeutics Shares Promising Phase 1 Trial Data for PRT3789 at International Symposium Read More
DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) recently showcased preliminary safety results for its WEE1 inhibitor, APR-1051, at the EORTC-NCI-AACR Symposium in Barcelona. This data comes from ACESOT-1051, a Phase …
Aprea Therapeutics Presents Promising Safety Data for WEE1 Inhibitor at International Symposium Read More
PHILADELPHIA, PA — Interius BioTherapeutics has taken a significant step forward with the dosing of its first participant in the Phase 1 clinical trial of INT2104, a pioneering gene therapy designed …
Interius BioTherapeutics Launches Innovative Gene Therapy Trial for B-Cell Malignancies Read More